NASDAQ:CLRB

Cellectar Biosciences Stock Forecast, Price & News

$1.24

+0.01 (+0.81 %)

(As of 10/19/2020 12:00 AM ET)

Add

Compare

Today's Range

$1.21

Now: $1.24▼

$1.25

50-Day Range

$1.06

MA: $1.20▼

$1.37

52-Week Range

$1.01

Now: $1.24▼

$3.33

Volume105,692 shs

Average Volume544,251 shs

Market Capitalization$33.02 million

P/E RatioN/A

Dividend YieldN/A

Beta1.56

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Cellectar Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.25, Cellectar Biosciences has a forecasted upside of 323.4% from its current price of $1.24.
Amount of Analyst Coverage
Cellectar Biosciences has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Cellectar Biosciences has received 223 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cellectar Biosciences has received 190 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cellectar Biosciences has received 54.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote “Outperform” if you believe CLRB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cellectar Biosciences does not currently pay a dividend.
Dividend Growth
Cellectar Biosciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.27% of the stock of Cellectar Biosciences is held by insiders.
Percentage Held by Institutions
Only 11.30% of the stock of Cellectar Biosciences is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Cellectar Biosciences are expected to grow in the coming year, from ($0.89) to ($0.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cellectar Biosciences is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cellectar Biosciences is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cellectar Biosciences has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.37 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CLRB

Previous Symbol

CUSIPN/A

CIK1279704

Webwww.cellectar.com

Phone608-441-8120

Employees8

Debt

Debt-to-Equity Ratio0.01

Current Ratio6.94

Quick Ratio6.94

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.84 per share

Price / Book1.48

Profitability

EPS (Most Recent Fiscal Year)($1.84)

Net Income$-14,090,000.00

Net MarginsN/A

Return on Equity-141.71%

Return on Assets-98.29%

Miscellaneous

Outstanding Shares26,627,000

Market Cap$33.02 million

Next Earnings Date11/10/2020 (Estimated)

OptionableNot Optionable

$1.24

+0.01 (+0.81 %)

(As of 10/19/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

How has Cellectar Biosciences' stock been impacted by Coronavirus?

Cellectar Biosciences' stock was trading at $1.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLRB stock has decreased by 31.1% and is now trading at $1.24.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Cellectar Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cellectar Biosciences.

When is Cellectar Biosciences' next earnings date?

Cellectar Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Cellectar Biosciences.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02.
View Cellectar Biosciences' earnings history.

When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work?

Shares of Cellectar Biosciences reverse split before market open on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CLRB?

4 Wall Street analysts have issued 1-year price targets for Cellectar Biosciences' stock. Their forecasts range from $3.00 to $10.00. On average, they anticipate Cellectar Biosciences' stock price to reach $5.25 in the next year. This suggests a possible upside of 323.4% from the stock's current price.
View analysts' price targets for Cellectar Biosciences.

Who are some of Cellectar Biosciences' key competitors?

Some companies that are related to Cellectar Biosciences include Sesen Bio (SESN), Inflarx (IFRX), Aytu BioScience (AYTU), Tyme Technologies (TYME), Sierra Oncology (SRRA), Oasmia Pharmaceutical AB (publ) (OASM), Adamas Pharmaceuticals (ADMS), Catalyst Biosciences (CBIO), vTv Therapeutics (VTVT), Pivot Pharmaceuticals (PVOTF), Strongbridge Biopharma (SBBP), Celyad Oncology (CYAD), Evoke Pharma (EVOK), Lumos Pharma (LUMO) and Catabasis Pharmaceuticals (CATB).
View all competitors.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International Co. (S.TO) (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals Inc. (HBM.TO) (HBM).

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the following people:

Mr. James V. Caruso, Pres, CEO & Director (Age 61, Pay $664.49k)
Mr. Dov Elefant, VP & CFO (Age 53, Pay $155.29k)
Mr. Jarrod Longcor, Chief Bus. Officer (Age 47, Pay $428.23k)
Dr. John E. Friend II, M.D., Chief Medical Officer (Age 50)
Gregory J. Lynch Esq., Sec.

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.76%). Company insiders that own Cellectar Biosciences stock include Dov Elefant, James V Caruso, Jarrod Longcor and Stephen A Hill.
View institutional ownership trends for Cellectar Biosciences.

Which institutional investors are buying Cellectar Biosciences stock?

CLRB stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Cellectar Biosciences stock in the last two years include Dov Elefant, James V Caruso, Jarrod Longcor, and Stephen A Hill.
View insider buying and selling activity for Cellectar Biosciences.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $1.24.

How big of a company is Cellectar Biosciences?

Cellectar Biosciences has a market capitalization of $33.02 million. The biopharmaceutical company earns $-14,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Cellectar Biosciences employs 8 workers across the globe.

What is Cellectar Biosciences' official website?

The official website for Cellectar Biosciences is www.cellectar.com.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings